We now have top line phase 3 data for retatrutide a triple (GIP, GLP-1, glucagon) agonist: At 40 weeks (efficacy estimand): ~16.8% weight loss ~1.9% A1c reduction We are entering a new phase: Multi-hormonal therapies Integrated obesity and diabetes care Precision approaches to cardiometabolic disease One pathway is not enough for a complex disease like obesity, and it is exciting to see a growing pipeline of therapies with distinct mechanisms
Longer term For longer protocols, review metabolic, kidney, liver, and cardiovascular trends every 3-6 months with a clinician
Today, most patients have both benefits: for example, Medicare beneficiaries have Part D (pharmacy) and Part B (medical), and private plans have dedicated pharmacy coverage and an overarching medical plan
Despite promising results in depression and anxiety, GLP-1 RAs have not shown significant benefits in improving cognitive functioning or psychosocial outcomes in schizophrenia or dementia, highlighting the need for cautious optimism and further investigation into their broader neuropsychiatric applications
Eligibility is built around two main pieces of information: your BMI and whether you have any weight-related comorbidities
doi:10.1177/2040622315620180 2